Combination of Anlotinib and PD-1/PD-L1 Inhibitors as Second-line and Subsequent Therapy in Advanced Small-cell Lung Cancer

被引：0
|
作者：
Yu, L. [1 ]
Xu, J. [1 ]
Qiao, R. [1 ]
Zhong, H. [1 ]
Han, B. [1 ]
Zhong, R. [1 ]
机构：
[1] Shanghai Jiao Tong Univ, Shanghai Chest Hosp, Shanghai, Peoples R China
来源：
JOURNAL OF THORACIC ONCOLOGY | 2022年 / 17卷 / 09期
关键词：
small-cell lung cancer; anlotinib; PD-1/PD-L1;
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
EP08.01-10
引用
收藏
页码：S391 / S392
页数：2
相关论文
共 50 条
  • [21] Efficacy and safety of PD-L1 inhibitors versus PD-1 inhibitors in first-line treatment with chemotherapy for extensive-stage small-cell lung cancer
    Hui Yu
    Ping Chen
    Xiuyu Cai
    Chen Chen
    Xuanye Zhang
    Lina He
    Yixin Zhou
    Shaodong Hong
    Bei Zhang
    Cancer Immunology, Immunotherapy, 2022, 71 : 637 - 644
  • [22] Thyroid dysfunction (TD) induced by PD-1/PD-L1 inhibitors in advanced lung cancer
    Wang, Yanling
    Yang, Xiaoxuan
    Ma, Jia
    Chen, Shenglan
    Gong, Ping
    Dai, Ping
    HELIYON, 2024, 10 (05)
  • [23] Soluble PD-L1 levels correlate with efficacy of PD-1/PD-L1 inhibitors in lung cancer
    Kang, Da Hyun
    Koh, Jeong Suk
    Chung, Chaeuk
    Park, Dongil
    Lee, Song-I
    Lee, Jeong Eun
    RESPIROLOGY, 2023, 28 : 99 - 99
  • [24] PD-1/PD-L1 inhibitors as a hope for smokers of non-small cell lung cancer patient
    Yu, Zhuo
    Zhang, Peiqing
    Gu, Weikuan
    Jiang, Xicheng
    TRANSLATIONAL CANCER RESEARCH, 2019, 8 (08) : 2941 - 2943
  • [25] PD-L1 expression and PD-1/PD-L1 inhibitors in breast cancer
    Monneur, Audrey
    Goncalves, Anthony
    Bertucci, Francois
    BULLETIN DU CANCER, 2018, 105 (03) : 261 - 272
  • [26] PD-1/PD-L1 Inhibitors in Cervical Cancer
    Liu, Yuncong
    Wu, Li
    Tong, Ruizhan
    Yang, Feiyue
    Yin, Limei
    Li, Mengqian
    You, Liting
    Xue, Jianxin
    Lu, You
    FRONTIERS IN PHARMACOLOGY, 2019, 10
  • [27] The influence of pharmaceutical care in patients with advanced non-small-cell lung cancer receiving combination cytotoxic chemotherapy and PD-1/PD-L1 inhibitors
    Kou, Wen
    Lin, Yan Yan
    Su, Fei
    Xiang, Yue
    Qiao, Hui
    Wu, Xin'An
    Hou, Xiao-Ming
    FRONTIERS IN PHARMACOLOGY, 2022, 13
  • [28] PD-L1 expression and EGFR status in advanced non-small-cell lung cancer patients receiving PD-1/PD-L1 inhibitors: a meta-analysis
    Li, Jing
    Gu, Jian
    FUTURE ONCOLOGY, 2019, 15 (14) : 1667 - 1678
  • [29] PD-1/PD-L1 Inhibitors as Monotherapy in the First-Line Treatment of Advanced Non-Small Cell Lung Cancer Patients with High PD-L1 Expression: An Expert Position Statement
    Isla, Dolores
    Sanchez, Alfredo
    Casal, Joaquin
    Cobo, Manuel
    Majem, Margarita
    Reguart, Noemi
    Zugazagoitia, Jon
    Bernabe, Reyes
    JOURNAL OF CLINICAL MEDICINE, 2023, 12 (15)
  • [30] PD-1/PD-L1 inhibitors
    Sunshine, Joel
    Taube, Janis M.
    CURRENT OPINION IN PHARMACOLOGY, 2015, 23 : 32 - 38
12345